KR20070034477A - 펩티드 화합물의 본태성 진전 및 기타 진전 증후군 치료를위한 신규한 용도 - Google Patents

펩티드 화합물의 본태성 진전 및 기타 진전 증후군 치료를위한 신규한 용도 Download PDF

Info

Publication number
KR20070034477A
KR20070034477A KR1020067025264A KR20067025264A KR20070034477A KR 20070034477 A KR20070034477 A KR 20070034477A KR 1020067025264 A KR1020067025264 A KR 1020067025264A KR 20067025264 A KR20067025264 A KR 20067025264A KR 20070034477 A KR20070034477 A KR 20070034477A
Authority
KR
South Korea
Prior art keywords
lower alkyl
tremor
unsubstituted
aryl
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020067025264A
Other languages
English (en)
Korean (ko)
Inventor
토마스 스퇴르
Original Assignee
쉬바르츠파르마에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉬바르츠파르마에이지 filed Critical 쉬바르츠파르마에이지
Publication of KR20070034477A publication Critical patent/KR20070034477A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020067025264A 2004-06-24 2005-06-22 펩티드 화합물의 본태성 진전 및 기타 진전 증후군 치료를위한 신규한 용도 Abandoned KR20070034477A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58208404P 2004-06-24 2004-06-24
US60/582,084 2004-06-24
PCT/EP2005/006750 WO2006000397A1 (en) 2004-06-24 2005-06-22 Novel use of peptide compounds for treating essential tremor and other tremor syndromes

Publications (1)

Publication Number Publication Date
KR20070034477A true KR20070034477A (ko) 2007-03-28

Family

ID=34970895

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067025264A Abandoned KR20070034477A (ko) 2004-06-24 2005-06-22 펩티드 화합물의 본태성 진전 및 기타 진전 증후군 치료를위한 신규한 용도

Country Status (19)

Country Link
US (1) US7427601B2 (https=)
EP (1) EP1758606A1 (https=)
JP (1) JP5038892B2 (https=)
KR (1) KR20070034477A (https=)
CN (1) CN1964733B (https=)
AR (1) AR049940A1 (https=)
AU (1) AU2005256468B2 (https=)
BR (1) BRPI0512622A (https=)
CA (1) CA2566301C (https=)
EA (1) EA013592B1 (https=)
IL (1) IL179732A0 (https=)
MX (1) MXPA06015010A (https=)
MY (1) MY146509A (https=)
NO (1) NO20070423L (https=)
NZ (1) NZ551207A (https=)
TW (1) TWI361693B (https=)
UA (1) UA88166C2 (https=)
WO (1) WO2006000397A1 (https=)
ZA (1) ZA200609021B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DK1243263T3 (da) * 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
AU2005232395B2 (en) 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EA014055B1 (ru) * 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EA019757B1 (ru) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
CA2672494A1 (en) * 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
US7747551B2 (en) * 2007-02-21 2010-06-29 Neurovista Corporation Reduction of classification error rates and monitoring system using an artificial class
US8829033B2 (en) 2009-09-23 2014-09-09 The University Of North Carolina At Chapel Hill N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
US20110281808A1 (en) * 2010-05-14 2011-11-17 Allmax Nutrition Inc. Composition and Method for Increasing Pre Workout Thermogenics
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
BR112013013525A2 (pt) 2010-12-02 2016-10-18 Ucb Pharma Gmbh formulação de liberação controlada sólida de lacosamida para administração oral, composição farmacêutica sólida, e, método para a prevenção, alívio e/ou tratamento de uma doença do sistema nervoso central
EP4233861A3 (en) * 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
IL154470A0 (en) * 2000-08-17 2003-09-17 Teva Pharma Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE60131032T2 (de) * 2000-08-25 2008-08-14 Research Corp. Technologies, Inc., Tucson Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne
AU2002224847A1 (en) 2000-11-21 2002-06-03 U C B, S.A. N-alkylated gaba compounds, processes for their preparation and their use as medicaments
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DK1243263T3 (da) 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
WO2004024096A2 (en) * 2002-09-13 2004-03-25 Eisai Co., Ltd. Method of treating tremors
CA2544467C (en) 2002-11-18 2014-02-18 John M. Stewart Paralytic peptide for use in neuromuscular therapy
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)

Also Published As

Publication number Publication date
CA2566301C (en) 2011-06-14
EP1758606A1 (en) 2007-03-07
US20050288234A1 (en) 2005-12-29
BRPI0512622A (pt) 2008-03-25
JP5038892B2 (ja) 2012-10-03
ZA200609021B (en) 2008-04-30
NO20070423L (no) 2007-03-22
MXPA06015010A (es) 2007-03-26
US7427601B2 (en) 2008-09-23
TW200603823A (en) 2006-02-01
AR049940A1 (es) 2006-09-13
AU2005256468B2 (en) 2010-12-09
UA88166C2 (ru) 2009-09-25
CA2566301A1 (en) 2006-01-05
IL179732A0 (en) 2007-05-15
JP2008503533A (ja) 2008-02-07
TWI361693B (en) 2012-04-11
WO2006000397A1 (en) 2006-01-05
CN1964733A (zh) 2007-05-16
EA200700108A1 (ru) 2007-06-29
EA013592B1 (ru) 2010-06-30
MY146509A (en) 2012-08-15
AU2005256468A1 (en) 2006-01-05
CN1964733B (zh) 2012-05-23
NZ551207A (en) 2010-07-30

Similar Documents

Publication Publication Date Title
KR20070034477A (ko) 펩티드 화합물의 본태성 진전 및 기타 진전 증후군 치료를위한 신규한 용도
EP1754476A1 (en) Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US6803481B2 (en) Use of peptide class of compound for treating non neuropathic inflammatory pain
JP5190334B2 (ja) アミノ酸鎮痙薬の新規用途
CA2565051C (en) Novel use of peptide compounds for treating dyskinesia
AU2002257681A1 (en) Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
US20060100157A1 (en) Novel use of peptide compounds for treating pain in painful diabetic neuropathy
CN100562312C (zh) 肽化合物用于治疗运动障碍的新用途
KR20070010168A (ko) 운동장애 치료를 위한 펩티드 화합물의 신규한 용도
HK1049960A (en) Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
KR20080038408A (ko) 근육통 치료를 위한 펩티드 화합물의 신규한 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20061130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100604

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20111128

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120725

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20111128

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20120824

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20120725

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20121022

Appeal identifier: 2012101007605

Request date: 20120824

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20120824

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20120824

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20120127

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20100604

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20121022

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20120926

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee